NEW YORK--(BUSINESS WIRE)--OMRIX Biopharmaceuticals, Inc. (“Omrix”) (NASDAQ: OMRI), a fully-integrated biopharmaceutical company that develops and markets biosurgical and immunotherapy products, announced today the appointment of Asaf Alperovitz, as Chief Financial Officer (CFO) effective October 23, 2008.
